Kalaris Therapeutics, Inc. 8-K

What Happened Kalaris Therapeutics, Inc. (KLRS) filed an 8-K on June 4, 2026 reporting the results of its 2026 Annual Meeting of Stockholders held June 3, 2026. Stockholders elected three Class III directors — Napoleone Ferrara, M.D., David Hallal and Leone Patterson — each to a three-year term expiring at the 2029 annual meeting. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, recommended annual frequency for future advisory votes on executive compensation, and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Director elections (terms to expire 2029):
  • Napoleone Ferrara, M.D.: For 15,619,403; Withheld 733,571; Broker non-votes 3,420,470.
  • David Hallal: For 15,623,189; Withheld 729,785; Broker non-votes 3,420,470.
  • Leone Patterson: For 15,858,093; Withheld 494,881; Broker non-votes 3,420,470.
• Say-on-pay (non-binding): For 15,852,844; Against 495,763; Abstain 4,366; Broker non-votes 3,420,470.
• Frequency of future advisory votes (non-binding): One Year 16,336,117; Two Years 875; Three Years 11,154; Abstain 4,827; Broker non-votes 3,420,470. The Board intends to hold advisory votes on executive compensation every year.
• Auditor ratification: Deloitte & Touche LLP ratified as independent auditor for 2026 — For 19,771,260; Against 1,583; Abstain 601.

Why It Matters These results confirm board continuity with three directors re-elected and maintain the current audit relationship with Deloitte, which affects annual financial reporting and oversight. The non-binding approval of executive compensation and the stockholders’ clear preference for annual advisory votes mean the company will continue to present say-on-pay proposals to shareholders every year, providing investors repeated opportunities to express views on management pay.